Form 4: CFO Gall Disposes iTeos Shares in Concentra Merger

iTeos Therapeutics CFO Matthew Gall disposed of all his beneficial ownership in the company following its acquisition by Concentra Biosciences for $10.047 per share plus a CVR.

Summary

• Matthew Gall, Chief Financial Officer of iTeos Therapeutics, Inc., reported the disposition of all his beneficial ownership in the company.
• The disposition occurred on August 29, 2025, as a result of the merger of iTeos Therapeutics with Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Concentra Biosciences LLC.
• Each outstanding share of iTeos common stock was converted into $10.047 in cash and one non-transferable contractual contingent value right (CVR).
• This transaction included 89,429 shares of common stock, which incorporated 65,000 restricted stock units that vested and were canceled.
• Additionally, 447,646 stock options were canceled. In-the-money options resulted in a cash payment based on the difference between the merger cash amount and the option exercise price, plus one CVR per underlying share.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger, providing a definitive exit value for shareholders and accelerated vesting for equity award holders. This is a neutral to slightly positive event for the involved parties, as it executes a pre-announced corporate action.

Positives

• The merger provided a cash payment of $10.047 per share to shareholders.
• Holders also received a Contingent Value Right (CVR), offering potential future value.
• Accelerated vesting of restricted stock units and stock options for eligible service providers, including the CFO, upon the merger.

Negatives

• iTeos Therapeutics, Inc. is no longer an independent publicly traded entity following the merger.
• Shareholders no longer hold direct equity in iTeos Therapeutics, Inc.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and depends on future events or performance milestones, which are not detailed in this filing.

Future Outlook

The filing indicates that holders of iTeos shares and certain equity awards received a non-transferable contractual contingent value right (CVR), the future value of which is dependent on undisclosed future events.

Industry Context

This filing indicates consolidation within the biotechnology or pharmaceutical sector, where smaller companies like iTeos Therapeutics are acquired by larger entities or private equity. Such mergers are common for companies with promising pipelines or technologies.

Comparison to Industry Standards

• The per-share cash consideration of $10.047, combined with a CVR, is a common structure in biotech acquisitions, allowing the acquirer to pay a base price and defer additional payments contingent on the achievement of specific clinical or regulatory milestones.
• The use of CVRs is a standard mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards, seen in deals like the acquisition of Reata Pharmaceuticals by Biogen or the acquisition of Acceleron Pharma by Merck.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, ending their direct equity ownership in iTeos.
• Employees (including management like CFO): Those with accelerated vesting provisions for equity awards benefited from immediate vesting and cash/CVR conversion.

Next Steps

• The value realization of the Contingent Value Rights (CVRs) will depend on future events or milestones, which are not detailed in this filing.

Key Dates

Keywords

iTeos Therapeutics, ITOS, Concentra Biosciences, Merger, Acquisition, Form 4, Insider Transaction, Matthew Gall, Chief Financial Officer, Stock Options, Restricted Stock Units, Contingent Value Right, CVR, Tender Offer